Group Leader, R&D NGS
DiaCarta Inc.
Pushpinder Kaur holds a Ph.D. in Biotechnology from Panjab University, Chandigarh, India. Her doctoral studies focused on the identification of single nucleotide polymorphism that confers increased susceptibility to lung cancer. She subsequently worked as a postdoc in cancer epigenetics at the International Agency for Research on Cancer (WHO), in France. She also worked as a Research Associate in cancer genetics and epigenetics at Oregon State University, Oregon, and the University of Southern California, Los Angeles. Following postdoctoral studies, she joined as a Senior Scientist in 2021 in DiaCarta Inc., a leading translational genomics and personalized diagnostic company. In her current role as a Group Leader, R&D NGS, she is involved in developing next-generation sequencing (NGS)-based panels for mutation and methylation for colorectal cancer diagnosis.